The mechanism of action of lenalidomide includes degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which act as central transcription factors regulating various genes involved in the survival of myeloma cells. Here, IKZF1 is linked to plasma cell myeloma.